shRNA clones for gene silencing
OmicsLink™ shRNA clone collections include lentiviral and non-viral vector-based shRNA constructs against genome-wide human, mouse and rat genes. shRNA of varying lengths (19 to 29 bases) were designed using a proprietary algorithm to make shRNA expression constructs that have high knockdown efficiency with minimal off-target effect.
-
Guaranteed shRNA knockdown
-
A set of four expression constructs is offered against every target gene with the guarantee that at least one of the four will have a knockdown effect of 70% or more on corresponding gene expression as determined by qRT-PCR, otherwise the constructs will be replaced one time free of charge
-
All cell types covered
-
Lentiviral and non-viral vector option allows transfection or transduction of shRNA into difficult-to-transfect cells as well conventional dividing cell lines.
-
Multiple delivery formats
-
shRNA are delivered as 4 individual constructs of 5 µg purified plasmid. Lentivirus for shRNA is also available as a part of custom services
-
Markers and reporters
-
Vectors with mCherry or eGFP reporter gene for monitoring transfection or transduction efficiencies. Stable cell selection with puromycin marker.
-
Fully sequenced expression cassettes
-
Expression cassettes of all shRNA clones are fully sequenced including the promoter, sense and antisense target sequences, hairpin, termination and other linker sequences.
-
Vector based shRNA clones0,00 €Vector based shRNA technology. Collection of shRNA expression clones available in both regular mammalian expression vector psi-H1™ and lentiviral expression systems (psiLv-H1™ and psiLV-U6™), which enables both transient and stable gene silencing. A mamma Learn More - Validated Human Kinome shRNA Clones0,00 €Vector based shRNA technology. Collection of validated human kinome shRNA expression clones available in both regular mammalian expression vector psi-H1™ and lentiviral expression systems (psiLv-H1™ and psiLV-U6™), which enables both transient and stable Learn More
-
-
-
-
-
-
-
-